NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo

Cancer Letters

Volumn 250, Issue 2, 2007, Pages 268-275

  Chu, Chao shun ^a,b   Xue, Bin ^a   Tu, Chen ^a   Feng, Zhen hua ^a   Shi, Yi huan ^a   Miao, Yi ^b   Wen, Chuan Jun ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Melanoma; Metastasis; MMP2; NRAGE; Pancreatic cancer

Indexed keywords

BETA CATENIN; GELATINASE A; MELANOMA ANTIGEN 1; SMALL INTERFERING RNA; UVOMORULIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; DNA PRIMERS; GENE SILENCING; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 34047099792     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.10.020     Document Type: Article

References (18)

1. Yoshida B.A., Sokoloff M.M., Welch D.R., and Rinker-Schaeffer C.W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl. Cancer Inst. 92 (2000) 1717-1730
2. Willett C.G., Czito B.G., Bendell J.C., and Ryan D.P. Locally advanced pancreatic cancer. J. Clin. Oncol. 23 (2005) 4538-4544
3. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., and Modiano M.R. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Clin. Oncol. 15 (1997) 2403-2413
4. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92 (2003) 827-839
5. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89 (1997) 1260-1270
6. Määttä M., Soini Y., Liakka A., and Autio-Harmainen H. Differential expression of Matrix Metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin. Cancer Res. 6 (2000) 2726-2734
7. Wen C.J., Xue B., Qin W.X., Yu M.Y., Zhang M.Y., Zhao D.H., Gao X., Gu J.R., and Li C.J. NRAGE, a human neurotrophin receptor interacting MAGE homologue, regulates p53 transcriptional activity and inhibits cell proliferation. FEBS Lett. 564 (2004) 171-176
8. Kendall S.E., Goldhawk D.E., Kubu C., Barker P.A., and Verdi J.M. Expression analysis of a novel p75NTR signaling protein, which regulates cell cycle progression and apoptosis. Mech. Dev. 117 (2002) 187-200
9. Salehi A.H., Roux P.P., Kubu C.J., Zeindler C., Tannis L.L., Verdi J.M., and Barker P.A. NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor dependent apoptosis. Neuron 27 (2000) 279-288
10. Williams M.E., Strickland P., Watanabe K., and Hinck L. UNC5H1 Induces Apoptosis via Its Juxtamembrane Region through an Interaction with NRAGE. J. Biol. Chem. 278 (2002) 17483-17490
11. Masuda Y., Sasaki A., Shibuya H., Ueno N., Ikeda K., and Watanabe K. Dlxin-1, a novel protein that binds Dlx5 and regulates its transcriptional function. J. Biol. Chem. 276 (2001) 5331-5338
12. Xue B., Wen C., Shi Y., Zhao D., and Li C. Human NRAGE disrupts E-cadherin/b-catenin regulated homotypic cell-cell adhesion. Biochem. Biophys. Res. Commun. 336 (2005) 247-251
13. Chung C.Y., Pallero M.A., Murphy-Ullrich J.E., Lauffenburger D.A., and Horwitz A.F. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell. 7 (1996) 883-892
14. Ellenrieder V., Alber B., Lacher U., Hendler S.F., Menke A., Boeck W., Wagner M., Wilda M., Friess H., BÜchler M., and Gress T.M. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int. J. Cancer 85 (2000) 14-20
15. Ito H., Gardner-Thorpe J., Zinner M.J., Ashley S.W., and Whang E.E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134 (2003) 221-226
16. Benlimame N., He Q., Jie S., Xiao D., Xu Y.J., Loignon M., Schlaepfer D.D., and laoui-Jamali M.A. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J. Cell Biol. 171 (2005) 505-516
17. Frame M.C. Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 117 (2004) 989-998
18. Tian X., Rai D., Li J., Zou C., Bai Y., Wazer D., Band V., and Gao Q. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res. 65 (2005) 4747-4753